LECOM Health is First in the Region to Provide Amyloid-Targeting Therapies to Treat Alzheimer’s Disease
FDA-approved treatments administered as intravenous infusions Erie, Pa. (March 18, 2025) — LECOM Health is the first healthcare provider in the Erie region to offer amyloid-targeting therapies (ATT), which are monoclonal antibodies aimed at the amyloid-beta cascade for the treatment of early symptomatic Alzheimer’s Disease. FDA-approved medications being administered are Leqembi and Kisunla, which target the biomarkers related to AD and potentially slow the decline of the disease. Medication is administered as a 30-minute to...Read More »
